FRIDAY, October 16, 2009 Poster Area
Poster Session P-2/4: CHEMOTHERAPY
Poster Commission Members: President: Viano I. (Novara) Members: Bertazzoni Minelli E. (Verona), D’Alessandro N. (Palermo)
(1 award)
Poster Session P-2/4: CHEMOTHERAPY
Poster Commission Members: President: Viano I. (Novara) Members: Bertazzoni Minelli E. (Verona), D’Alessandro N. (Palermo)
(1 award)
| THYMOL INHIBITS GARDNERELLA VAGINALIS ADHESION TO HUMAN VAGINAL CELLS Braga P., Dal Sasso M., Spallino A., Culici M., Sturla C. (Milano, Gallarate VA) |
NEW HPLC–MS METHOD FOR THE SIMULTANEOUS QUANTIFICATION IN HUMAN PLASMA OF THE ANTILEUKEMIA DRUGS IMATINIB, DASATINIB, AND NILOTINIB De Francia S., D'Avolio A., De Martino F., Pirro E., Piccione F., Racca S., Di Carlo F. (Orbassano TO, Torino) |
| MITOTANE: THE IMPORTANCE OF THE MONITORING IN ADRENOCORTICAL CANCER PATIENTS De Martino F., De Francia S., Pirro E., Piccione F., Terzolo M., Daffara F., Di Carlo F., Raschi E., Poluzzi E., Motola D., Moretti U., De Ponti F., Barberis A., Marino S., Géloen A., Lysenko V., Mancardi D., Merlino A., Di Carlo F., Mognetti B., Bolego C., Buccellati C., Folco G., Gaion R., Sala A., Marino S., Portigliatti Barbos M., Barberis A., Di Carlo F., Mognetti B., Bolego C., Buccellati C., Folco G., Gaion R., Sala A. (Orbassano TO) |
| ANTI-ENDOTHELIAL EFFECTS OF LOW DOSE CERAMIDE ANALOGS IN VITRO AND IN VIVO Fioravanti A., Orlandi P., Di Desidero T., Canu B., Danesi R., Del Tacca M., Bocci G. (Pisa) |
| IRINOTECAN AND AXITINIB SYNERGISTICALLY INHIBIT PANCREATIC CANCER IN VITRO AND IN VIVO BYMODULATING VEGFR-2,ABCG2AND ATP7A GENE EXPRESSION AND TSP-1 SECRETION Canu B., Fioravanti A., Di Desidero T., Orlandi P., Danesi R., Del Tacca M., Bocci G. (Pisa) |
| THE IGF1R INHIBITOR NVP-AEW541 DISRUPTS A PRO-SURVIVAL AND PRO-ANGIOGENIC IGF-STAT3-HIF1 PATHWAY IN HUMAN GLIOBLASTOMA CELLS. Ravizza R., Molteni R., Monti E., Gariboldi M. (Busto Arsizio VA) |
| MODULATION OF MMP-9 IN U87MG GLIOBLASTOMA CELLS BY A3 ADENOSINE RECEPTORS Gessi S., Sacchetto V., Fogli E., Merighi S., Varani K., Baraldi P., Tabrizi M., Leung E., Mac Lennan S., Borea P. (Ferrara, Cary) |
| THERMODYNAMICS OF A2B ADENOSINE RECEPTOR BINDING DISCRIMINATES AGONISTIC FROM ANTAGONISTIC BEHAVIOUR Sacchetto V., Gessi S., Fogli E., Varani K., Merighi S., Leung E., MacLennan S., Borea P. (Ferrara, Cary) |
| GEMCITABINE-LOADED PEGYLATED UNILAMELLAR LIPOSOMES VS GEMZAR®: BIODISTRIBUTION, PHARMACOKINETIC FEATURES AND IN VIVO ANTITUMOR ACTIVITY D'Agostino M., Paolino D., Cosco D., Celano M., Racanicchi L., Trapasso E., Celia C., Iannone M., Puxeddu E., Costante G., Russo D., Fresta M. (Catanzaro, Milano, Messina, Roccelletta di Borgia CZ, Perugia) |
| CORRELATION BETWEEN IN VITRO AND IN VIVO CYTIDINE DEAMINASE PHENOTYPE AND GEMCITABINE PHARMACOKINETICS IN PATIENTS WITH SOLID TUMORS Gusella M., Modena J., Barile C., Toso S., Bononi A., Menon D., Pasini F., Padrini R. (Rovigo, Padova) |
| PRELIMINARY IN VITRO BIOLOGICAL EVALUATIONS OF NEW PRODRUGS DESIGNED AS ANTIMELANOMA AGENTS. Nassi A., Ruzza P., Rosato A., Rondina M., Rossi C., Floreani M., Quintieri L. (Padova) |
| CURCUMIN INCREASES SENSITIVITY OF RESISTANT OVARIAN TUMOUR CELLS TO PLATINUM DRUGS: APOPTOTIC EFFECTS AND CELL-CYCLE ALTERATIONS. montopoli m., ragazzi e., froldi g., dorigo p., caparrotta l. (Padova) |
| AN EVALUATION OF ANTIBIOTIC USE AND RESISTANCE IN AN ITALIAN UNIVERSITY HOSPITAL Silvani M., Poluzzi E., Motola D., Biagi C., Nanetti A., Ambretti S., Fiacchi P., Puggioli C., Vaccheri A., Montanaro N. (Bologna) |
| IN VITRO INVESTIGATION OF SULINDAC DERIVATIVES AS POTENTIAL ANTICANCER AGENTS Fogli S., Banti I., Digiacomo M., Macchia M., Lapucci A., Breschi M. (Pisa) |
| HPβCDS COMPLEXING RESVERATROL: A NOVEL APPROACH FOR CHEMOPREVENTION OF SQUAMOUS CELL CARCINOMA. Salamone P., Sprio A., Di Scipio F., Marinos L., Cavalli R., Carlotti M., Sapino S., Di Carlo F., Berta G. (Orbassano TO, Torino) |
| HISTONE DEACETYLASE (HDAC) INHIBITION MODULATES INTRACELLULAR DEOXYNUCLEOTIDES (DNTP) POOLS AND POTENTIATES THE ANTITUMOR EFFECTS OF THE RIBONUCLEOTIDE REDUCTASE (RR) INHIBITOR 3’-METHYL-ADENOSINE (3’-ME- Meli M., Tolomeo M., Grifantini M., Mai A., Cappellacci L., Franchetti P., Saiko P., Dusonchet L. (Palermo, Camerino MC, Roma, Vienna) |
| THE MGLU3 RECEPTOR ANTAGONIST, LY341495, ENHANCES CHEMOSENSITIVITY OF COLORECTAL CANCER STEM CELLS TO STANDARD CYTOTOXIC CHEMOTHERAPY Mosillo P., Turriziani B., Ricci-Vitiani L., Ciceroni C., Cappuccio I., Spinsanti P., Sale P., Nicoletti F., Melchiorri D. (Roma, Pavia, Pozzilli IS) |
| THERAPEUTIC DRUG MONITORING OF DAPTOMICYN: DEVELOPMENT, VALIDATION AND APPLICATION OF A HPLC METHOD Polillo M., Di Paolo A., Tascini C., Lastella M., Gemignani G., Ciofi L., Taddei R., Menichetti F., Danesi R., Del Tacca M. (Pisa) |
| PHARMACOKINETICS AND TOXICITY OF AN EARLY SINGLE INTRAVESICAL INSTILLATION OF MITOMYCIN-C AFTER ENDOSCOPIC RESECTION OF SUPERFICIAL BLADDER CANCER. Mattioli F., Campodonico F., Fucile C., Marini V., Maffezzini M., Martelli A. (Genova) |
| DECOLONIZATION OF S. AUREUS CARRIERS IN ORTHOPEDIC SURGICAL TEAM MEMBERS: IMPACT ON SURGICAL SITE INFECTIONS PORTIGLIATTI BARBOS M., BARBERIS A., MARINO S., PECORARO S., PICCO W., VEGLIO V., DI CARLO F., MOGNETTI B. (Orbassano TO, Torino) |